ZyVersa is developing a novel drug therapy, VAR 200, expected to attenuate progression of FSGS to kidney failure. Learn the status of its development: https://bit.ly/43JXTIg
ZyVersa Therapeutics Inc.
制药业
Weston，FL 1,011 位关注者
Restoring Health, Transforming Lives Through Innovation
关于我们
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.
- 网站
-
http://www.zyversa.com
ZyVersa Therapeutics Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Weston，FL
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Drug Development、Orphan Disease、Nephrology和Immunology
地点
ZyVersa Therapeutics Inc.员工
-
Peter Wolfe
CFO Director Financial Planning and Analysis with P&L Management Expertise | Open to New Opportunities
-
Greg Freitag
Board Member: PDS Biotechnology Company (NASDAQ: PDSB) and ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA)
-
Karen Cashmere
Chief Commercial Officer at ZyVersa Therapeutics Inc.
-
Steve Glover
Co-Founder, Chairman, Chief Executive Officer at ZyVersa Therapeutics
动态
-
Rare kidney disease experts and FDA collaborated to identify a robust surrogate endpoint to shorten FSGS drug trials. Learn more: https://bit.ly/43JXTIg
-
FSGS, a devastating, rare kidney disorder, is a leading cause of kidney failure with no effective drug therapies. Learn why. https://bit.ly/43JXTIg
-
Learn the effects of inflammasome inhibition on body weight and fasting blood glucose in the obesity-associated cardiomyopathy animal model: https://bit.ly/3FEMQGf
-
Learn what our CEO said about the importance of inhibiting multiple inflammasome pathways with IC 100 in cardiovascular diseases: https://bit.ly/3FEMQGf
-
-
Inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function in obesity-related cardiomyopathy. See the supportive data: https://bit.ly/3FEMQGf
-
Inflammasome inhibition reduces inflammation. Learn about its additional role in affecting metabolic activity in Alzheimer’s disease: https://bit.ly/4bMzpjr
-
Learn what our CEO said about data assessing the potential of Inflammasome ASC Inhibitor IC 100 in Parkinson’s disease: https://bit.ly/4bMzpjr
-
-
Inflammasome inhibition reduces neuroinflammation and brain deposition of amyloid beta contributing to Alzheimer’s disease progression. Learn how: https://bit.ly/4bMzpjr
-
Learn about the metabolic improvements seen with inflammasome inhibition: http://bit.ly/41FrfWL